| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 12.99% | B of A Securities | $4 → $2 | Downgrades | Neutral → Underperform |
| 06/27/2023 | 12.99% | Goldman Sachs | $16 → $2 | Maintains | Sell |
| 06/27/2023 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 06/26/2023 | 125.99% | B of A Securities | $29 → $4 | Downgrades | Buy → Neutral |
| 06/26/2023 | 521.47% | Stifel | $28 → $11 | Downgrades | Buy → Hold |
| 06/26/2023 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 06/26/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 06/02/2023 | — | Stifel | Upgrades | Hold → Buy | |
| 02/28/2023 | 1312.43% | Cowen & Co. | $15 → $25 | Maintains | Market Perform |
| 02/23/2023 | 803.95% | Goldman Sachs | $9 → $16 | Maintains | Sell |
| 02/21/2023 | 803.95% | Goldman Sachs | $9 → $16 | Maintains | Sell |
| 01/31/2023 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 01/26/2023 | 1877.4% | Raymond James | → $35 | Upgrades | Market Perform → Outperform |
| 01/05/2023 | 1425.42% | B of A Securities | $18 → $27 | Upgrades | Neutral → Buy |
| 11/08/2022 | 408.47% | Goldman Sachs | $8 → $9 | Maintains | Sell |
| 05/24/2022 | 351.98% | Goldman Sachs | $9 → $8 | Maintains | Sell |
| 03/01/2022 | 408.47% | Goldman Sachs | $10 → $9 | Maintains | Sell |
| 09/22/2021 | 521.47% | Goldman Sachs | $16 → $11 | Downgrades | Neutral → Sell |
| 08/20/2021 | — | Raymond James | Upgrades | Underperform → Market Perform | |
| 08/10/2021 | 1594.92% | SVB Leerink | $35 → $30 | Maintains | Outperform |
| 07/16/2021 | 1538.42% | B of A Securities | → $29 | Downgrades | Buy → Neutral |
| 07/16/2021 | 1538.42% | Stifel | $55 → $29 | Downgrades | Buy → Hold |
| 04/07/2021 | 1538.42% | Mizuho | → $29 | Downgrades | Buy → Neutral |
| 04/07/2021 | 3063.84% | SVB Leerink | $64 → $56 | Maintains | Outperform |
| 04/07/2021 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 04/07/2021 | — | JP Morgan | Upgrades | Underweight → Neutral | |
| 03/31/2021 | 2555.37% | B of A Securities | → $47 | Upgrades | Neutral → Buy |
| 03/02/2021 | 3515.82% | SVB Leerink | $91 → $64 | Maintains | Outperform |
| 03/02/2021 | 2442.37% | Jefferies | $75 → $45 | Downgrades | Buy → Hold |
| 02/01/2021 | 3176.84% | HC Wainwright & Co. | → $58 | Initiates Coverage On | → Buy |
| 11/06/2020 | 5097.74% | SVB Leerink | $90 → $92 | Maintains | Outperform |
| 10/26/2020 | — | Raymond James | Initiates Coverage On | → Underperform | |
| 09/08/2020 | 4984.75% | SVB Leerink | $84 → $90 | Maintains | Outperform |
| 08/07/2020 | 4645.76% | SVB Leerink | $80 → $84 | Maintains | Outperform |
| 05/08/2020 | 4419.77% | SVB Leerink | $85 → $80 | Maintains | Outperform |
| 05/01/2020 | 2159.89% | Cowen & Co. | → $40 | Initiates Coverage On | → Market Perform |
| 04/27/2020 | 2442.37% | B of A Securities | → $45 | Initiates Coverage On | → Neutral |
| 08/26/2019 | 3572.32% | Mizuho | → $65 | Maintains | Buy |
| 05/29/2019 | 2442.37% | Goldman Sachs | → $45 | Assumes | → Neutral |
| 05/10/2019 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 04/12/2019 | 3572.32% | Piper Sandler | → $65 | Initiates Coverage On | → Neutral |
| 02/11/2019 | 3911.3% | Stifel | → $71 | Reinstates | → Buy |
| 12/19/2018 | 3911.3% | Citigroup | → $71 | Upgrades | Neutral → Buy |
| 10/15/2018 | 4645.76% | Leerink Swann | $82 → $84 | Maintains | Outperform |
What is the target price for FibroGen (FGEN)?
The latest price target for FibroGen (NASDAQ: FGEN) was reported by B of A Securities on August 8, 2023. The analyst firm set a price target for $2.00 expecting FGEN to rise to within 12 months (a possible 12.99% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for FibroGen (FGEN)?
The latest analyst rating for FibroGen (NASDAQ: FGEN) was provided by B of A Securities, and FibroGen downgraded their underperform rating.
When is the next analyst rating going to be posted or updated for FibroGen (FGEN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of FibroGen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for FibroGen was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating FibroGen (FGEN) correct?
While ratings are subjective and will change, the latest FibroGen (FGEN) rating was a downgraded with a price target of $4.00 to $2.00. The current price FibroGen (FGEN) is trading at is $1.77, which is out of the analyst's predicted range.
